Febridx doesn't appear to have CMS, which is medicare coverage,...

Febridx doesn't appear to have CMS, which is medicare coverage, and I haven't seen any evidence of private payors coming on board. So reimbursement still isn't in place from what I can see. Once you get CMS coverage, this creates impetus for Private Payors to come on board with policy coverage. Many just piggyback I imagine. I expect that individual cases will take place where an insurer might cover a certain hospital or clinic that has a path lab.

Febridx does have a CPT PLA code, and path labs only, can purchase the units quoting their CLIA licence number. There is a long way to go from here, but all the requirements are in place to more to CMS.

It does not hurt to have doctors and hospitals and other medical associations requesting the coverage, and the test being written into clinical guidelines by relevant expert panels, such as:
https://www.idsociety.org/ - sets clinical guidelines
https://www.cdc.gov/respiratory-viruses/guidance/index.html
https://www.nfid.org/infectious-diseases/
https://aspe.hhs.gov/collaborations-committees-advisory-groups/carb

This lack of reimbursement is not unexpected for me, and makes a lot of sense at current levels of revenue etc - these are further catalysts to come, and was one of the reasons I thought the BARDA news was so critical and impressive. Having CMS assigning a payment rate will be a huge catalyst for the share price from here. If they get a CLIA waiver, that will be a boomer too.

If the Pasteur bill gets up that will be up to $6 billion towards fighting antibiotic resistance. I have no idea if it will - but it is a reminder to politicians at least, and generates ideas to save money and improve the situation even without that bill.